Ethicon Exec: FDA Mesh Safety Notice Could Have Long-Term Impact
This article was originally published in The Gray Sheet
Executive Summary
A manufacturer of surgical mesh devices for minimally invasive gynecological procedures is worried that a recent FDA safety alert may slow long-term adoption of the products even after better data is available
You may also be interested in...
Surgical mesh alert
FDA warns physicians and consumers Oct. 20 about complications associated with surgical mesh devices to treat pelvic organ prolapse and stress urinary incontinence. The agency said it received more than 1,000 reports from nine manufacturers of problems with transvaginal placement of the mesh devices, including erosion through vaginal epithelium, infection, pain and urinary problems. Physicians should obtain specialized training in mesh placement techniques and monitor for complications, FDA advises. The agency also warned consumers about problems with surgical mesh for hernia repairs
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.